NASDAQ:CYCC

Delisted

Cyclacel Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy CYCC

*Your capital is at risk

$6.37

+0 (+0%)

At Close: Dec 10, 2025

Cyclacel Pharmaceuticals Q2 EPS $(0.11) Up From $(0.16) YoY

12:00am, Tuesday, 13'th Aug 2019

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

07:46pm, Sunday, 11'th Aug 2019

Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s re

Cyclacel Pharmaceuticals Announces First Patient Treated In Phase 1/2 Study Of Sapacitabine And Venetoclax In Relapsed Or Refractory AML Or MDS Patients

12:00am, Monday, 22'nd Jul 2019

Mixed shelf filing roundup - healthcare

12:00am, Wednesday, 05'th Jun 2019

50 Biggest Movers From Friday

12:00am, Tuesday, 28'th May 2019

A Look At Benzinga Pro's Most-Searched Tickers For May 24

12:00am, Friday, 24'th May 2019

Cyclacel Pharmaceuticals Q1 EPS $(0.12) Beats $(0.2) Estimate

12:00am, Tuesday, 14'th May 2019

New Research: Key Drivers of Growth for Conatus Pharmaceuticals, MasTec, Cyclacel ...

12:00am, Friday, 19'th Apr 2019

Cyclacel Pharma Give an Updated From Phase 1 Data

12:00am, Monday, 01'st Apr 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

12:00am, Saturday, 30'th Mar 2019

The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO

12:00am, Thursday, 28'th Mar 2019

Cyclacel Pharmaceuticals FY18 EPS $(0.62) vs $(1.95) In FY17, Collaboration, R&D Sales $150K

12:00am, Wednesday, 27'th Mar 2019

Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

12:00am, Tuesday, 26'th Mar 2019

41 Stocks Moving In Monday's Mid-Day Session

04:51pm, Monday, 25'th Mar 2019

Cyclacel Pharma shares are trading higher after the company announced an independent investigation was published on the company's treatment.

12:00am, Monday, 25'th Mar 2019

Cyclacel Pharmaceuticals Stock News

Cyclacel Pharmaceuticals Q2 EPS $(0.11) Up From $(0.16) YoY

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Cyclacel Pharmaceuticals Announces First Patient Treated In Phase 1/2 Study Of Sapacitabine And Venetoclax In Relapsed Or Refractory AML Or MDS Patients

Mixed shelf filing roundup - healthcare

50 Biggest Movers From Friday

A Look At Benzinga Pro's Most-Searched Tickers For May 24

Cyclacel Pharmaceuticals Q1 EPS $(0.12) Beats $(0.2) Estimate

New Research: Key Drivers of Growth for Conatus Pharmaceuticals, MasTec, Cyclacel ...

Cyclacel Pharma Give an Updated From Phase 1 Data

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO

Cyclacel Pharmaceuticals FY18 EPS $(0.62) vs $(1.95) In FY17, Collaboration, R&D Sales $150K

Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

41 Stocks Moving In Monday's Mid-Day Session

Cyclacel Pharma shares are trading higher after the company announced an independent investigation was published on the company's treatment.

Top Fintech Company